A Study of Isoprinosine in Patients With Severe AIDS

Newport Pharmaceuticals International

Overview

To evaluate the effect of Isoprinosine in patients diagnosed as having AIDS relative to: Laboratory (immunologic defects): * Comparison of total helper and suppressor T-cell numbers among the groups. * Comparison of changes in natural killer cell activity. * Comparison of other laboratory findings among the groups. Clinical changes: * Comparison of the frequency of opportunistic infections among the groups. * Comparison of the frequency of the development of AIDS-related malignancies. * Comparison of other clinical manifestations relative to severity and time of onset.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

DOUBLE

Conditions

HIV Infections

Interventions

Inosine pranobexDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Exclusion Criteria Co-existing Condition: Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer are excluded. Concurrent Medication: Excluded: * Steroids. * Cytotoxic immunosuppressive agents. * Radiotherapy. The following are excluded: * Critically ill patients. * Patients receiving steroids, cytotoxic immunosuppressive agents, radiotherapy. * Patients who have received any other immunotherapy. * Patients with a history of gout, urolithiasis, nephrolithiasis, renal dysfunction, and severe gastric ulcer. Prior Medication: Excluded: * Any other immunotherapy. Patients with severe AIDS and specified laboratory immunologic defects.

Locations (1)

Newport Pharmaceuticals International Inc

Laguna Hills, California, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.